OR WAIT null SECS
Regulatory agencies published guidelines to advance drug development, streamline submission processes, and promote biosimilars.
FDA issued guidance documents that address patient-centric drug development, biosimilars, and a variety of biologics application guidelines. The US Pharmacopeial Convention (USP) also proposed some changes to monographs. A few notable actions taken this year are reviewed.
eBook: Regulatory Sourcebook, September 2019
When referring to this article, please cite it as Pharmaceutical Technology Editors, “What’s New in Regulations and Compliance," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2019).